National Surveillance of Pediatric Pertussis in Ambulatory Settings

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

Since 2002, Whooping cough surveillance in pediatric private practice has been set up in France. The results of the first years, 2002-2006, have confirmed the effectiveness of the Pertussis whole-cell (Pw) vaccine and in particular the duration of protection of 9/10 years. After evaluating cases in children vaccinated with Pw vaccines, the study aims today to analyze cases in children vaccinated with Pertussis acellular (Pa) vaccines used since 2002/2003 and to assess, on an outpatient basis, the impact of new vaccine recommendations in France (in 2013, introduction of a 2 + 1 schedule - 8 weeks, 4 months and a 11-month recall - and a 6-year recall, and in 2014, update in the recommendations of exams to be prescribed based on the child's age and vaccination status).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 1 day
Maximum Age: 18
View:

• All children under 18 years old with a pertussis diagnosis is suspected and a biological exam is requested

Locations
Other Locations
France
ACTIV
RECRUITING
Créteil
Contact Information
Primary
Corinne Levy, MD
corinne.levy@activ-france.fr
0033148850404
Backup
Stéphane Béchet, MsC
stephane.bechet@activ-france.fr
0033148850404
Time Frame
Start Date: 2001-05-30
Estimated Completion Date: 2030-01-01
Participants
Target number of participants: 898
Related Therapeutic Areas
Sponsors
Leads: Association Clinique Thérapeutique Infantile du val de Marne
Collaborators: Merck Sharp & Dohme LLC, Sanofi, GlaxoSmithKline

This content was sourced from clinicaltrials.gov